AllDocs -> cancers

Kidney cancer The kidneys are part of the urinary system. The human body has two kidneys, one on either side of the middle of the back, just under the ribs. The kidneys: • Remove waste products from the blood. • Produce hormones that regulate blood pressure, control the body's calcium levels, and trigger the production of red blood cells in bones. Around 85 per cent of kidney cancers are renal cell carcinomas. Cancer cells initially grow in the lining of one or both kidneys. Without treatment, the cancer may spread to other areas of the body. Kidney cancer is more common in people over the age of 55 years. It is more common in men than women. About 500 Victorians are diagnosed with kidney cancer every year. Symptoms In its early stages, kidney cancer may have no symptoms. The disease may be discovered by accident, when the ...

= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = If you need this information in another language or medium (audio, large print, etc) please contact the Patient Advice & Liaison Service (PALS) on 0800 374 208 email: palservice@salisbury .nhs.ìâ . You are entitled to a copy of any letter we write about you. Please ask if you want one when you come to the hospital.= Author: P Manktelow Date written: Aug 05 Approved: Aug 05 Review date: Aug 08 Code: Snew94 We ...

EUROPEAN COMMISSION DIRECTORATE-GENERAL JOINT RESEARCH CENTRE Institutional and scientific relations Public Relations JRC fact sheet Profiling kidney cancer using DNA macroarrays The Joint Research Centre (JRC), a Directorate-General of the European Commission, uses DNA macroarray technology to identify specific gene patterns to diagnose renal cell carcinoma. Preliminary results indicate complex genetic mechanisms are involved in kidney cancer . This research could help identify DNA characteristics, leading to a better molecular understanding of renal tumours, and accelerate identification of new prognostic markers or therapeutic targets. Renal cell carcinoma (RCC) comprises 3% of cancer malignancies worldwide, and is increasing. Only a fraction of RCCs respond to radio-, immuno-, or chemotherapy, making control difficult once spread beyond ...

Yes 1 UCLA KIDNEY CANCER PROGRAM HEALTH QUESTIONNAIRE NAME UCLA NO. (Leave blank if not yet assigned) DATE OF BIRTH SOC. SEC. NO. Dear Patient: This questionnaire is designed to help your doctors know your general medical history and to save you time during your initial evaluation. Because the information is important for your health care, please fill out carefully and completely. Thank you for your cooperation. SEX: Male Female MARITAL STATUS: Single Married Separated Divorced Widowed A. GENERAL CONDITION 1. My height is _. 2. My weight is _. 3. My regular weight is . 4. My current health allows me to: (Choose the single most appropriate response) a. Be fully active and carry on all normal activity.. b. Perform activities such as light house work, office work, shopping, etc., but not to perform strenuous ...

Chapter 18: Kidney cancer 173 Kidney cancer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

AM PM Shown at actual size Getting the Facts About Your Treatment for Kidney Cancer What is Nexavar? Nexavar ® (sorafenib) tablets is a prescription, anticancer medicine used to treat adults with kidney cancer , also known as renal cell carcinoma (RCC). Your cancer specialist has prescribed Nexavar to help treat your cancer . How do I take Nexavar? Nexavar is a pill that should be taken by mouth and swallowed whole. It is usually taken as two 200-mg tablets twice a day. It is important to take Nexavar exactly as your doctor has prescribed. Do not chew Nexavar. You should take Nexavar with water on an empty stomach (at least 1 hour before or 2 hours after a meal). What if I miss a dose of Nexavar? If you miss a dose of Nexavar, skip the missed dose, and take your next dose at your regular time. Do not double your ...

of the file http://www.mediadoctor.ca/documents/01%20Aug,%202006.%20CBC.ca--Nexavar.doc . G o o g l e automatically generates html versions of documents as we crawl the web. To link to or bookmark this page, use the following url: http://www.google.com/search?q=cache:GinxzUessYoJ:www.mediadoctor.ca/documents/01%2520Aug,%25202006.%2520CBC.ca--Nexavar.doc+kidney+cancer+filetype:pdf+OR+filetype:doc+OR+filetype:ppt+OR+filetype:xls+OR+filetype:rtf&hl=it&ct=clnk&cd=25&lr=lang_en Google is neither affiliated with the authors of this page nor responsible for its content. These search terms have been highlighted: kidney cancer New treatment approved for kidney cancer 01 August 2006; CBC.ca Health Canada has approved a new drug for advanced kidney cancer , the first new treatment option for the disease in more than a decade. Renal cell carcinoma is ...

Cancer in Northern Ireland 1993 - 2001: A Comprehensive Report 105 18: Cancer of the Kidney (C64-C66, C68) Incidence In 2001, cancer of the kidney was the tenth most common cancer in males and the thirteenth commonest in females. On average, 99 males and 65 females were diagnosed as having cancer of the kidney each year, accounting for about 2% of male and 1% of female cancers. Age Given the levels of disease in 2001, the risk of getting cancer of the kidney before the age of 75 years was 1 in 85 for males and 1 in 172 for females (Table 18a). Fifty percent of males were diagnosed under the age of 67 years, whilst for females it was 68 years. The average annual incidence for cancer of the kidney rose in males and females up to 70-74 years, with the age- specific rates consistently higher in males (Figure 18a). Prevalence In Northern Ireland on 31st December 2001, there ...

Nexavar ® Approved by European Commission for the Treatment of Advanced Kidney Cancer West Haven, CT and Emeryville, CA – July 23, 2006 – Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the European Commission has granted marketing authorization to Nexavar ® (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer , who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Bayer will commercialize Nexavar in Europe. “Today’s approval of Nexavar, which has shown to double progression-free survival, is a significant advance in the fight against kidney cancer ,” said Dr. Gunnar Riemann, Head of Bayer HealthCare's Pharmaceuticals Division. “For more than a decade, Europeans with kidney ...

Survival of Cancer Patients in Northern Ireland 1993-96 57 Incidence and Mortality In 1996, cancer of the kidney was the tenth most common cancer in males and the sixteenth most common cancer in women, accounting for over 2% and 1% of all cancers registered in men and women respectively. Between 1993 and 1996, an average of 108 men and 62 women were registered annually as having cancer of the kidney , whilst approximately 42 men and 23 women died each year from this disease. There were no statistically significant (P>0.05) trends in either the incidence or mortality EASRs for men or women (Figure 13.1). Table 13.1: Summary table for cancer of the kidney Summary 1993-1996 Males Females Average annual number of kidney cancers registered 108 62 Average annual number of kidney cancer deaths 42 23 % cases excluded from survival analysis ...

Issue 65 Spring 2006 10 State Cancer Legislative Database Update, NCI Adopted Resolutions (n=4) Governor’s s Proclamations (n=2) Introduced/Pending Measures (n=5) Legislative Data Byte It is predicted that more than 38,000 new cases of kidney cancer will be diagnosed in the United States during 2006. 1 Kidney cancer develops most often in people over the age of 40 and occurs twice as often in males as in females,but no one knows the exact causes of this disease. 2 There are more than 100,000 kidney cancer survivors living in the United States. 3 Often, kidney cancers are found "incidentally," meaning that the cancer is found during medical tests for some other illness such as gallbladder disease. 1 However,because the symptoms of kidney cancer can often be mistaken for signs of ...

Kidney Cancer Vaccine Shows Promise in Trial Sunday February 22, 2004 (1521 PST) ISLAMABAD, February 23 (Online): An experimental vaccine against kidney cancer has shown promising results in reducing the recurrence of the disease, German researchers said. Kidney cancer occurs mostly in adults over 40 and accounts for about three percent of all cancers. About 32,000 new cases are diagnosed each year in the United States alone. In a trial of 379 kidney cancer patients, scientists showed that the vaccine made by German biotechnology company LipoNova improved disease-free survival of patients. "For the first time ever it has been shown that additional therapy after surgery for kidney tumors is effective," said Dr Christian Doehn of the University of Lubeck Medical School in Germany. Five-year survival rates were 77 percent for patients who were given six injections ...

kidney cancer Nexavar ® Approved by European Commission for the Treatment of Advanced Kidney Cancer West Haven, CT and Emeryville, CA - July 2006 - Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the European Commission has granted marketing authorization to Nexavar ® (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer , who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Bayer will commercialize Nexavar in Europe. “Today's approval of Nexavar, which has shown to double progression-free survival, is a significant advance in the fight against kidney cancer ,” said Dr. Gunnar Riemann, Head of Bayer HealthCare's Pharmaceuticals Division. “ For more than ...

Abstract. In a limited study, comprising only ten patients, we have previously reported that allogeneic irradiated RCC-cell-line cells, engineered to produce IL-2 (ACHN-IL-2), admixed with autologous metastat- ic formalin-treated tumour cells were used to vaccinate MRCC patients in progression of disease and also receiving IL-2 immunotherapy. The cells, admixed to autologous TC, were administered subcutaneously. We now report an extended study on thirty patients and one hundred thirty-one controls. Patients received 4ñ20 injections (mean 10 ± 4), containing an average of 92 × 10 6 ± 45 × 10 6 ACHN-IL-2 transfected cells (a mini- mum of 25 × 10 6 , and a maximum of 200 × 10 6 ). Autologous TC, admixed to allogeneic, were also administered by 4ñ16 s.c. injections (mean 7 ± 3), i.e. a ...

KIDNEY CANCER (ADULT) - RENAL CELL CARCINOMA - All Sections KIDNEY CANCER (ADULT) - RENAL CELL CARCINOMA What Is Cancer ? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer , they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells develop because of damage to DNA. This substance is in every cell and directs all its activities. Most of the time when ...

(formalin fixed) A214: Kidney and ureter cancer tissues For research use only Specifications: • No. of cases: 31 • Tissue type: Kidney and ureter cancer tissues ( kidney :28, ureter:3) • No. of spots: 2 spots from each cancer case (62 spots) 6 non-neoplastic spots (6 spots) • Total spots: 68 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 Summary of tissue spots (formalin fixed) A214: Kidney and ureter cancer tissues For research use only No. Sex Age KeyWord Grade TNM Stage 1 1,2 M 45 RCC.conventional type 1 T1aN0M0 (I) 2 3,4 ...

Therapies targeted for kidney cancer Posted 5/31/2006 9:32 PM ET By Liz Szabo, USA TODAY Adele Weiland is an expert on kidney cancer medications. After all, she has tried most of them. Doctors have prescribed one experimental therapy after another over the past three years. Although nothing has cured her disease, each drug has kept her alive long enough to try the next new medication. "I know something is going to get me one of these days," says Weiland, 70, of Columbus, Ohio, whose disease has spread to her pancreas, liver and small intestine. "But 10 years ago, I wouldn't have all these options." After decades of relatively little progress against kidney cancer , researchers are testing a small arsenal of new drugs, says William Li, president of Angiogenesis Foundation, a non-profit organization devoted to developing new therapies. The Food and Drug Administration ...

Association of Northern California Oncologists is pleased to sponsor two talks for oncologists entitled NEW TARGETED AGENTS FOR KIDNEY CANCER with David R. Minor, M.D. & Sandy Srinivas, M.D. Medical Director California Kidney Cancer Center Assistant Professor of Medicine Assistant Clinical Professor Stanford University University of California, San Francisco ABSTRACT Two new agents, sorafenib and sunitinib, have recently been approved by the United States Food and Drug Administration for use in metastatic kidney cancer . Dr. Srinivas will discuss sorafenib and the upcoming ECOG adjuvant trial. Dr. Minor will discuss sunitinib as well as the implications of the new agents for patient selection for high-dose IL-2. These talks are scheduled for: 6:30PM Dinner • 7:00PM Lecture Tuesday, June 20 th ...

Saturday June 10, 2006 • ACCREDITATION The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION The University of Miami Leonard M. Miller School of Medicine designates this educational activity for a maximum of 8 AMA PRA Category 1 credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity. DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION All conflicts of interest of any individual(s) in a position to control the content of this CME Activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to the learners. ACKNOWLEDGMENTS ...

191 V OLUME 4, N UMBER 4 ¦ A PRIL 2006 www.SupportiveOncology.net J Support Oncol 2006;4:191–199 © 2006 Elsevier Inc. All rights reserved. Q U A L I T Y - O F - L I F E O U T C O M E S Abstract The Functional Assessment of Cancer Therapy (FACT)– Kidney Symptom Index (FKSI) was developed and validated to enhance treat- ment decision-making,practice guidelines,symptom management,and treatment efficacy for kidney cancer patients.Thirty-four symptoms re- lated to the disease were identified and tested. An equal weighting of patient and clinician ratings of the relative importance of each of these items led to production of a 15-item index (FKSI–15) and a 10-item ab- breviated option (FKSI–10).To assess psychometric properties, patients completed the FKSI, Functional Assessment of Cancer Therapy–General ...

Progress in the Treatment of Kidney Cancer Presented by Ronald M. Bukowski, MD The Cleveland Clinic Foundation Keith Lyons, MSW Cancer Care Find out about: • Current treatment options • New advances • The role of clinical trials • Ways to cope with cancer Help and Hope KIDNEY CANCER Page 2 National Office Cancer Care 275 Seventh Avenue New York, NY 10001 Email: teled@cancercare.org Services Tel: 212-712-8080 1-800-813-HOPE (4673) Administration Tel: 212-712-8400 Fax: 212-712-8495 Email: info@cancercare.org Website: www.cancercare.org Cancer Care is a national nonprofit organization that provides free professional support services to anyone affected by cancer : people with cancer , caregivers, children, loved ones, and the ...

Proceedings of the Virtual Conference on Genomics and Bioinformatics 2 Comparisons of Protein Profiles in Kidney Cancer Tissues and Their Primary Cell Cultures 1 Shi; T. 1 Dong, F. 1,2 Liou, L.S. 3 Duan, Z.-H. 2 Novick, A.A. 1* DiDonato, J.A. 1 Department of Cancer Biology 2 Urological Institute Cleveland Clinic Foundation Cleveland, OH 44195 3 Department of Computer Science University of Akron Akron, OH 44325 United States Of America É (216) 444-8178 *Correspondence should be addressed to: didonaj@ccf.org ABSTRACT We profiled the protein expressions in renal cell carcinoma (RCC) tissues and patient-matched normal kidney tissues using two-dimensional polyacrylamide gel ...

Questions and Answers 1. Q. Why did the Massachusetts Department of Public Health (MDPH) recommend conducting a follow-up study of the people diagnosed with kidney cancer in the South End of New Bedford? A. The results of the previous MDPH cancer study indicated that most of the cancer types evaluated occurred at or near the expected rates during 1982 through 1998 in New Bedford with the exception of kidney cancer . The study results showed a concentration of five individuals with kidney cancer living in close proximity to the Rodney Metals and Brittany Dye facilities. At the time of the investigation, MDPH did not have enough information about important risk factors for the disease, such as family medical history, occupational exposure, and history of smoking, making it difficult to assess the role that environmental exposures may have played in the development of kidney cancer . ...

Kidney Cancer What are the Kidneys? The kidneys are two bean-shaped organs located behind the abdomen on each side of the spine. The main job of the kidneys is to filter the blood and rid the body of liquid waste through the bladder. They also control the production of red blood cells and regulate blood pressure. What is Kidney Cancer? In adults, the most common type of kidney cancer is renal cell carcinoma which begins in the cells that line the small tubes (tubules) within the kidneys. It accounts for more than 90 percent of cancerous kidney tumors. Children are more likely to develop a kind of kidney cancer called Wilms’ tumor. What are the risk factors? Cigarette smoking increases the risk of developing renal cell carcinoma by about 40 percent. The risk decreases after smoking stops. Other risks include ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN KIDNEY CANCER TISSUE ARRAY Catalog Number: TMA-130 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed (Normal kidney tissue array) Cases: 21 Cores: 54 Diameter: 1.5mm Thickness: 5 µm Standard IHC: CK confirmed Layout : 6 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN KIDNEY CANCER TISSUE ARRAY Catalog Number: TMA-128 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed ( Kidney carcinoma tissue array) Cases: 23 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: CK confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN KIDNEY CANCER TISSUE ARRAY Catalog Number: TMA-131 Each dot represents a NORMAL tissue spot from one individual specimen that was selected and pathologically confirmed (Normal kidney tissue array) Cases: 70 Cores: 72 Diameter: 1.5mm Thickness: 5 µm Standard IHC: Villin confirmed Layout : 8 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 E ...